Thông tin thuốc gốc
Chỉ định và Liều dùng
Deep vein thrombosis, Pulmonary embolism
Adult: Treatment: Initially, 15 mg bid for 3 weeks. Maintenance: 20 mg once daily. Prophylaxis of recurrent cases: 10 mg once daily following completion of at least 6 months of anticoagulant treatment or 20 mg once daily in patients with high risk of recurrence.

Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation
Adult: 20 mg once daily, with the evening meal.

Prophylaxis of postoperative venous thromboembolism
Adult: 10 mg once daily starting 6-10 hours after surgery. Duration of treatment: 5 weeks (major hip surgery); 2 weeks (major knee surgery).

Prophylaxis of cardiovascular events in high-risk patients
Adult: In patients with coronary or peripheral artery disease in combination with aspirin: 2.5 mg bid.
Suy thận
Prophylaxis of postoperative venous thromboembolism; Prophylaxis of cardiovascular events in high-risk patients:
CrCl (mL/min)

Deep vein thrombosis; Pulmonary embolism:

CrCl (mL/min)
<15 Contraindicated. 
15-50 Initially, 15 mg bid for 3 weeks, followed by 20 mg once daily. May reduce maintenance dose to 15 mg once daily if risk of bleeding outweighs risk of recurrence.

Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation:
CrCl (mL/min) Dosage
<15 Contraindicated. 
15-50 15 mg once daily.
Suy gan
Moderate to severe (Child-Pugh class B and C): Contraindicated.
Cách dùng
10-mg tab: May be taken with or without food.
15- & 20-mg tab: Should be taken with food.
Chống chỉ định
Active pathological bleeding, lesions or conditions at increased risk of major haemorrhage (e.g. recent gastrointestinal ulceration, recent brain or spinal injury or surgery, recent intracranial haemorrhage). Renal impairment (CrCl <15 mL/min) or undergoing dialysis. Moderate to severe hepatic impairment (Child-Pugh Class B and C) or hepatic disease associated with coagulopathy. Pregnancy and lactation. Concomitant use with azole-antimycotics (e.g. ketoconazole) or HIV protease inhibitors (e.g. ritonavir); other anticoagulants such as heparin (e.g. enoxaparin, dalteparin), heparin derivatives (e.g. fondaparinux) or oral anticoagulants (e.g. warfarin, dabigatran, apixaban).
Thận trọng
Patient with risks of bleeding (e.g. bacterial endocarditis, congenital or acquired bleeding disorders, vascular retinopathy, uncontrolled severe hypertension, bronchiectasis or history of pulmonary bleeding); significant rheumatic heart disease, prosthetic heart valves. Renal impairment (CrCl 15-50 mg/mL). Avoid abrupt discontinuation in the absence of alternative treatment.
Tác dụng không mong muốn
Significant: Bleeding (e.g. as epistaxis, gingival, genitourinary bleeding), anaemia (prolonged use).
Gastrointestinal disorders: Abdominal pain.
Injury, poisoning and procedural complications: Wound secretion.
Investigations: Increased serum transaminases.
Musculoskeletal and connective tissue disorders: Back pain, limb pain.
Nervous system disorders: Dizziness.
Skin and subcutaneous tissue disorders: Pruritus.
Potentially Fatal: Major bleeding, post haemorrhagic anaemia.
Thông tin tư vấn bệnh nhân
This drug may cause syncope and dizziness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor renal function and CBC prior to initiation of therapy and at least annually; LFT; signs of bleeding.
Quá liều
Symptoms: Haemorrhagic complications. Management: Symptomatic and supportive treatment. Activated charcoal may be given to reduce absorption within 8 hours of ingestion.
Tương tác
Increased risk of bleeding with NSAIDs (e.g. aspirin), antiplatelet agents (e.g. clopidogrel), SSRI, and serotonin-norepinephrine reuptake inhibitors (SNRI). Decreased serum concentration with strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital).
Potentially Fatal: Increased plasma concentration and increased risk of bleeding with CYP3A4 and P-gp inhibitors (e.g. ketoconazole, itraconazole, voriconazole, posaconazole); HIV protease inhibitors (e.g. ritonavir); other anticoagulants such as unfractionated heparin, low molecular weight heparin (e.g. enoxaparin, dalteparin), heparin derivatives (e.g. fondaparinux), oral anticoagulants (e.g. warfarin, dabigatran, apixaban).
Tương tác với thức ăn
Decreased serum concentration with St. John’s wort.
Ảnh hưởng đến kết quả xét nghiệm
Prolonged clotting in PT, aPTT, HepTest and anti-factor Xa activity.
Tác dụng
Description: Rivaroxaban is an anticoagulant which selectively and directly inhibits factor Xa (activated factor X) in both the intrinsic and extrinsic pathways of the blood coagulation cascade thereby, inhibiting thrombin formation and development of thrombi. Factor Xa converts prothrombin to thrombin leading to fibrin clot formation and platelet activation.
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: Approx 80-100%. Time to peak plasma concentration: 2-4 hours.
Distribution: Crosses placenta and enters breastmilk. Volume of distribution: Approx 50 L. Plasma protein binding: Approx 92-95%, mainly to albumin.
Metabolism: Metabolised in the liver by CYP3A4/5 and CYP2J2 via oxidative degradation and hydrolysis.
Excretion: Via urine (66%; approx 36% as unchanged drug, 30% as inactive metabolites); faeces (28%; 7% as unchanged drug, 21% as inactive metabolites). Elimination half-life: 5-9 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Rivaroxaban, CID=9875401, https://pubchem.ncbi.nlm.nih.gov/compound/Rivaroxaban (accessed on Jan. 23, 2020)

Bảo quản
Store below 30°C.
Phân loại MIMS
Thuốc kháng đông, chống kết dính tiểu cầu & tiêu sợi huyết
Phân loại ATC
B01AF01 - rivaroxaban ; Belongs to the class of direct factor Xa inhibitors. Used in the treatment of thrombosis.
Tài liệu tham khảo
Anon. Rivaroxaban. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/09/2014.

Buckingham R (ed). Rivaroxaban. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2019.

Joint Formulary Committee. Rivaroxaban. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2019.

McEvoy GK, Snow EK, Miller J et al (eds). Rivaroxaban. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/09/2014.

Xarelto Tablet (Janssen Ortho LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/08/2019.

Xarelto Tablets. U.S. FDA. https://www.fda.gov/. Accessed 01/09/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Rivaroxaban từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Xarelto 10mg
  • Xarelto 15mg/Xarelto 20mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in